Related Experiment Video
Updated: Aug 10, 2026

Electrochemiluminescence Assays for Human Islet Autoantibodies
Published on: March 23, 2018
[Study on the postive frequency and distribution of glutamic acid decarboxylase antibody in phenotypic type 2
Xia Li1, Zhi-guang Zhou, Gan Haung
1Diabetes Centre, Institute of Metabolism and Endocrinology, Xiangya Second Hospital, Central South University, Changsha 410011, China.
Objective:
To investigate the positive frequency and distribution of glutamic acid decarboxylase antibody(GAD-Ab) in phenotypic type 2 diabetic(T2DM) patients.
Methods:
Sera of 2035 phenotypic T2DM patients were screened for GAD-Ab with radioligand assay. The positive frequency of GAD-Ab and its relation with clinical features were analyzed.
Results:
(1) The positivity of GAD-Ab in clinic-based, phenotypic T2DM patients was 7.1% (145/2035), comparable to that of data from Caucasians as shown by UKPDS(8.7% vs. 9.8%, P = 0.391) and ADOPT (8.0% vs. 4.2%, P = 0.000) but higher than that of Japanese in Ehime study(7.1% vs. 3.8%, P = 0.000). (2) The positive frequency and distribution of GAD-Ab titer were related to clinical features, including age at onset, body mass index (BMI) and fasting C peptide levels. Patients with younger age at onset (0.33 vs. 0.11, P < 0.05), less BMI (0.34 vs. 0.10, P < 0.05) and lower C peptide levels (0.38 vs. 0.11, P < 0.05) would have higher GAD-Ab titers.
Conclusion:
(1)The positivity of GAD-Ab in adult-onset phenotypic T2DM in Chinese was similar to that of Caucasians but higher than that of the Japanese. (2) The distribution of GAD-Ab titers was associated with clinical features, with high GAD-Ab titers for those having younger age at onset, less BMI and lower C peptide levels.
More Related Videos
Related Concept Videos
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis
Type I Diabetes I: Introduction
Diabetes Mellitus: Type 2 and Gestational
Type II Diabetes I: Introduction
Type I Diabetes II: Pathophysiology
Type II Diabetes II: Pathophysiology

